Key Points
- CFO Patrick Williams bought 11,891 NeuroPace shares for about $99,171, increasing his stake by 17.61% to 79,399 shares. The article also reports a similar-sized purchase by CEO Joel Becker.
- Analyst views are mixed: NeuroPace has a consensus Hold rating and a $13.11 average price target, while several firms recently cut ratings or targets.
- A law firm has announced an investigation into potential securities-law violations concerning the company’s changing 2026 revenue outlook, creating legal and reputational uncertainty.
NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) CFO Patrick Williams purchased 11,891 shares of NeuroPace stock in a transaction dated Tuesday, November 17th. The shares were bought at an average price of $8.34 per share, for a total transaction of $99,170.94. Following the acquisition, the chief financial officer owned 79,399 shares in the company, valued at approximately $662,187.66. This trade represents a 17.61% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
NeuroPace Trading Up 2.9%
Shares of NPCE stock opened at $8.20 on Wednesday. The company has a current ratio of 5.26, a quick ratio of 4.09 and a debt-to-equity ratio of 5.15. NeuroPace, Inc. has a twelve month low of $5.46 and a twelve month high of $19.60. The company's 50-day moving average price is $12.94 and its 200-day moving average price is $14.67. The stock has a market cap of $282.49 million, a price-to-earnings ratio of -14.64 and a beta of 1.98.
Wall Street Analysts Forecast Growth
Several equities analysts have weighed in on the stock. Raymond James Financial set a $21.00 target price on shares of NeuroPace in a report on Tuesday, September 15th. JPMorgan Chase & Co. downgraded shares of NeuroPace from an "overweight" rating to a "neutral" rating and cut their price target for the stock from $20.00 to $9.00 in a report on Friday, November 13th. Wolfe Research lowered shares of NeuroPace from a "strong-buy" rating to a "hold" rating in a research report on Monday. Wells Fargo & Company lowered shares of NeuroPace from an "overweight" rating to an "equal weight" rating and reduced their price target for the company from $19.00 to $9.00 in a research report on Friday, November 13th. Finally, HC Wainwright decreased their price objective on NeuroPace from $20.00 to $12.00 and set a "buy" rating on the stock in a report on Monday. Five investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, NeuroPace currently has a consensus rating of "Hold" and a consensus target price of $13.11.
Check Out Our Latest Analysis on NPCE
Trending Headlines about NeuroPace
These are some of the NPCE headlines that stood out recently:
- Positive Sentiment: CEO Joel Becker bought 11,891 shares for about $99,300, increasing his stake by 8.62%. SEC filing
- Neutral Sentiment: Brokerages’ reported average price target is $20.50, suggesting significant potential upside from the recent share level, though targets can change and are not guarantees. Brokerage price target report
- Negative Sentiment: A law firm announced an investigation into potential securities-law violations related to NeuroPace raising its 2026 revenue outlook in August and then lowering it to $91–$92 million the following quarter. The announcement creates legal and reputational uncertainty. Investigation notice
Hedge Funds Weigh In On NeuroPace
Several large investors have recently made changes to their positions in the stock. Soleus Capital Management L.P. boosted its position in shares of NeuroPace by 10.5% during the 3rd quarter. Soleus Capital Management L.P. now owns 3,218,000 shares of the company's stock worth $44,280,000 after purchasing an additional 306,878 shares during the period. Entropy Technologies LP acquired a new stake in NeuroPace in the 3rd quarter valued at approximately $146,000. Diversified Trust Co acquired a new stake in NeuroPace in the 3rd quarter valued at approximately $153,000. First Light Asset Management LLC raised its position in NeuroPace by 16.3% in the second quarter. First Light Asset Management LLC now owns 2,861,167 shares of the company's stock valued at $45,464,000 after purchasing an additional 401,201 shares during the period. Finally, Bank of America Corp DE purchased a new stake in NeuroPace in the second quarter valued at approximately $322,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.
NeuroPace Company Profile
(
Get Free Report)
NeuroPace, Inc. is a medical technology company focused on treating people with drug-resistant epilepsy. Its primary product is the RNS System, an implanted responsive neurostimulation device designed to detect patterns of abnormal electrical activity in the brain and deliver stimulation in response. The RNS System includes a neurostimulator implanted in the skull and leads placed in or near seizure-onset areas of the brain. Clinicians use the system to review brain activity and adjust treatment, while patients can use accompanying tools to record information about their seizures and share it with their care team.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].